A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab

Abstract

IntroductionAnti-tumor necrosis factor-alpha (TNF-α) treatments have been available for over two decades to treat inflammatory arthropathies (IA). Most of these disorders are common among women of reproductive age, which emphasizes the need to evaluate their safety in pregnancy. ObjectiveThis study aims to scrutinize neonatal and pregnancy outcomes in pregnant IA patients treated with adalimumab. Materials and methodsThe current cross-sectional work was conducted by reviewing the medical files of pregnant IA patients (n=30) receiving adalimumab referred to Golestan Hospital in Ahvaz (Iran) from 2014 to 2017, followed by extracting demographic profiles as well as neonatal and pregnancy outcomes. ResultsNoteworthy among the findings were PsA (n=13), RA (n=5), IBD (n=4), AS (n=3), uveitis (n=2), Behcet's disease (n=2), and panuveitis (n=1). The mean age of subjects, duration of illness, and duration of treatment were estimated at 29.53±5.88, 2.85±1.15, and 1.96±.90 years, respectively. No delivery outcome was found for 27 (90%) cases, and delivery outcomes observed in three (10%) patients were abortion (n=2) and preterm complications (n=1). No neonatal complication was found for 28 (93.3%) cases and neonatal IUGR outcome was reported in 2 (6.7%) cases. Cesarean section was a delivery method in 7 (23.3%) cases and natural method in 21 (70%) cases. There were no significant differences for the prevalence of cesarean section and neonatal outcomes based on the type of disease, but differences were observed for the outcome of delivery based on the type of disease. ConclusionAccording to our findings, definitive conclusions on the safety of adalimumab during pregnancy were impossible and there is a need for further research with a larger sample size.